We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · December 01, 2020

Sequential Eribulin vs Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients With Operable HER2-Negative Breast Cancer

The Oncologist

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Oncologist
A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients With Operable HER2-Negative Breast Cancer
Oncologist 2020 Nov 03;[EPub Ahead of Print], B Lim, J Song, NK Ibrahim, KB Koenig, M Chavez-MacGregor, JE Ensor, JS Gomez, S Krishnamurthy, AS Caudle, SF Shaitelman, GJ Whitman, V Valero

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading